Therapeutic significance of long noncoding RNAs in estrogen receptor‐positive breast cancer

Abstract

AbstractAbout 70% of cases of breast cancer are compromised by Estrogen‐positive breast cancer. Through its regulation of several processes, including cell proliferation, cell cycle progression, and apoptosis, Estrogen signaling plays a pivotal role in the genesis and progression of this particular kind of breast cancer. One of the best treatment strategies for treating Estrogen‐positive breast cancer is blocking Estrogen signaling. However, patients' treatment failure is mainly caused by the emergence of resistance and metastases, necessitating the development of novel therapeutic targets. Numerous studies have shown long noncoding RNAs (lncRNAs) to play a role in Estrogen‐mediated carcinogenesis. These lncRNAs interact with co‐regulators and the Estrogen signaling cascade components, primarily due to Estrogen activation. Vimentin and E‐cadherin are examples of epithelial‐to‐mesenchymal transition markers, and they regulate genes involved in cell cycle progression, such as Cyclins, to affect the growth, proliferation, and metastasis of Estrogen‐positive breast cancer. Furthermore, a few of these lncRNAs contribute to developing resistance to chemotherapy, making them more desirable targets for enhancing results. Thus, to shed light on the creation of fresh approaches for treating this cancer, this review attempts to compile recently conducted studies on the relationship between lncRNAs and the advancement of Estrogen‐positive breast cancer.